Royal Bank of Canada Sells 4,615 Shares of Cooper Companies Inc (COO)

Royal Bank of Canada cut its stake in shares of Cooper Companies Inc (NYSE:COO) by 4.3% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 103,762 shares of the medical device company’s stock after selling 4,615 shares during the quarter. Royal Bank of Canada’s holdings in Cooper Companies were worth $23,739,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Point72 Asset Management L.P. bought a new position in shares of Cooper Companies in the 1st quarter worth about $52,195,000. Renaissance Technologies LLC raised its position in shares of Cooper Companies by 103.9% in the 4th quarter. Renaissance Technologies LLC now owns 422,848 shares of the medical device company’s stock worth $92,130,000 after acquiring an additional 215,448 shares in the last quarter. Millennium Management LLC raised its position in shares of Cooper Companies by 110.9% in the 4th quarter. Millennium Management LLC now owns 391,217 shares of the medical device company’s stock worth $85,238,000 after acquiring an additional 205,755 shares in the last quarter. Ceredex Value Advisors LLC bought a new position in shares of Cooper Companies in the 1st quarter worth about $37,336,000. Finally, FIL Ltd raised its position in shares of Cooper Companies by 54.7% in the 1st quarter. FIL Ltd now owns 419,791 shares of the medical device company’s stock worth $96,053,000 after acquiring an additional 148,477 shares in the last quarter. 96.85% of the stock is currently owned by hedge funds and other institutional investors.

In related news, Director Michael Kalkstein sold 1,715 shares of the business’s stock in a transaction dated Wednesday, April 11th. The stock was sold at an average price of $221.66, for a total value of $380,146.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Allan E. Rubenstein sold 1,000 shares of the business’s stock in a transaction dated Friday, June 15th. The shares were sold at an average price of $235.13, for a total value of $235,130.00. Following the completion of the sale, the director now directly owns 4,568 shares of the company’s stock, valued at $1,074,073.84. The disclosure for this sale can be found here. Insiders sold a total of 3,145 shares of company stock valued at $716,039 over the last ninety days. 1.60% of the stock is currently owned by corporate insiders.

Several research analysts have recently weighed in on COO shares. Stephens reissued a “hold” rating and issued a $270.00 price objective on shares of Cooper Companies in a research report on Friday, March 9th. TheStreet raised Cooper Companies from a “c+” rating to a “b-” rating in a research report on Friday, June 15th. ValuEngine raised Cooper Companies from a “sell” rating to a “hold” rating in a research report on Friday, June 15th. Zacks Investment Research lowered Cooper Companies from a “buy” rating to a “hold” rating in a research report on Monday, May 21st. Finally, Oppenheimer set a $265.00 price objective on Cooper Companies and gave the stock a “hold” rating in a research report on Thursday, March 29th. Nine equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Cooper Companies has a consensus rating of “Hold” and a consensus target price of $265.36.

Shares of Cooper Companies opened at $235.45 on Friday, Marketbeat.com reports. Cooper Companies Inc has a one year low of $216.47 and a one year high of $260.26. The stock has a market capitalization of $11.56 billion, a P/E ratio of 21.52, a PEG ratio of 1.85 and a beta of 0.61. The company has a debt-to-equity ratio of 0.77, a current ratio of 2.76 and a quick ratio of 1.67.

Cooper Companies (NYSE:COO) last issued its earnings results on Thursday, June 7th. The medical device company reported $2.86 EPS for the quarter, beating analysts’ consensus estimates of $2.84 by $0.02. Cooper Companies had a return on equity of 17.14% and a net margin of 5.58%. The business had revenue of $631.30 million during the quarter, compared to analyst estimates of $627.49 million. During the same period in the previous year, the company posted $2.50 EPS. The firm’s revenue was up 20.8% compared to the same quarter last year. analysts expect that Cooper Companies Inc will post 11.81 EPS for the current fiscal year.

Cooper Companies Company Profile

The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.

Want to see what other hedge funds are holding COO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cooper Companies Inc (NYSE:COO).

Institutional Ownership by Quarter for Cooper Companies (NYSE:COO)

Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply